Medicinal and edible homologous fermentation composition, preparation method thereof and application of medicinal and edible homologous fermentation composition in preparation of products for protecting brain health

Through the medicinal and food homologous fermentation composition, probiotics fermentation of medicinal and food homologous raw materials are used to inhibit the activity of acetylcholinesterase and promote the secretion of neurotransmitters, solving the problems of poor effect and side effects of the brain sub-health products in the prior art. The effect of improving sleep and cognitive function is achieved.

CN118892518APending Publication Date: 2024-11-05HEBEI YIRAN BIOLOGICAL TECH CO LTD

Patent Information

Application Number
CN202410932002.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Most of the existing health care products for brain sub-health have a single mechanism, which has poor results, and the use of chemical drugs or single mechanism products has side effects, making it difficult to effectively improve brain nerve function and sleep problems.

Method used

Using medicinal and food homologous fermentation compositions, a composition that can inhibit acetylcholinesterase activity and promote neurotransmitter secretion is prepared by fermenting medicinal and food homologous raw materials, including Cistanche salmonella, Polygonatum, Pueraria pilosula, etc. and Nagqu. 4580 probiotics for improving sleep and cognitive function.

Benefits of technology

Significantly increase the content of acetylcholine, protect nerve cells, promote the secretion of dopamine and BDNF, improve symptoms such as sleep, memory and emotional instability, avoid side effects of chemical drugs, improve cognitive ability and memory, and is suitable for people with sub-healthy brains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004939984720000011
    Figure HDA0004939984720000011
  • Figure HDA0004939984720000012
    Figure HDA0004939984720000012
  • Figure HDA0004939984720000021
    Figure HDA0004939984720000021
Patent Text Reader

Abstract

The invention belongs to the technical field of microorganisms and traditional Chinese medicines, and relates to a medicinal and edible homologous fermentation composition, a preparation method thereof and application of the medicinal and edible homologous fermentation composition in preparation of products for protecting brain health. The raw materials for preparing the medicinal and edible fermentation composition comprise a medicinal and edible composition and compound probiotics Nanqu 4580, wherein the medicinal and edible composition comprises cistanche, rhizoma polygonati, radix puerariae, codonopsis pilosula, citron, fructus lycii, raw liquorice, longan aril, spina date seeds, red dates and raw hawthorn. The medicinal and edible homologous fermentation composition provided by the invention not only can reduce the generation of malondialdehyde, but also has the effects of protecting and repairing nerve cells, can promote the secretion of cell neurotransmitter dopamine and neurotrophic factor BDNF, and can inhibit the activity of acetylcholin esterase. The invention can be applied to products for resisting oxidation, improving sleep, improving memory, preventing cognitive competence decline or improving cognitive function, and has wide potential application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of Chinese herbal medicine and microorganisms, and in particular relates to a medicine-food homologous fermentation composition, a preparation method thereof, and an application thereof in preparing a product for protecting brain health. Background Art

[0003] With the change of lifestyle and pace of life, the number of people with sub-healthy brain is increasing. An unhealthy lifestyle causes the brain to be overloaded for a long time, making it difficult for people to enter a good learning and working state. A long-term sub-healthy brain state may lead to brain nerve dysfunction. When the brain nerves are dysfunctional, patients will experience symptoms such as difficulty falling asleep, insomnia, frequent dreams and easy awakening, which will further manifest as easy mistakes, decreased learning ability and memory. Long-term high pressure in life and work will induce anxiety and depression. If the disease progresses further, cognitive impairment may occur, seriously affecting life and work. However, the existing health care for brain sub-health is mostly a single mechanism to improve the above symptoms, but most of them are not effective. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention provides a medicinal and edible fermentation composition made from medicinal and edible raw materials fermented by probiotics, aiming to provide a composition product that can supplement neurotrophy, protect and repair nerve cells, promote neurotransmitter secretion, and inhibit acetylcholinesterase activity and increase acetylcholine content. It is intended to prevent, delay, and improve cognitive and other brain and nervous system functions through multiple mechanisms such as improving sleep, protecting / repairing nerve cells, inhibiting acetylcholinesterase activity, and promoting the secretion of cellular neurotransmitters dopamine and neurotrophic factor BDNF, avoiding the limitations and side effects of using chemical drugs or single-mechanism products.

[0005] Another object of the present invention is to provide a method for preparing the above-mentioned medicine-food fermentation composition, which has a simple preparation method, high production efficiency, and is conducive to industrial production.

[0006] The present invention also has a purpose, which is to provide the application of the above-mentioned medicine-food fermentation composition, which can not only inhibit the activity of acetylcholinesterase and reduce oxidative stress, but also protect and repair nerve cells and promote the secretion of neurotransmitter dopamine and neurotrophic factor BDNF, so it has a wide range of potential uses.

[0007] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a medicinal and edible fermentation composition, the raw materials of which include a medicinal and edible composition and a compound probiotic;

[0009] The medicine-food composition is composed of the following raw materials in parts by weight: 90-180 parts of Cistanche deserticola, 36-72 parts of Polygonatum sibiricum, 36-54 parts of Pueraria root, 45-65 parts of Codonopsis pilosula, 18-27 parts of Citron, 18-27 parts of Lycium barbarum, 18-27 parts of raw Licorice root, 18-27 parts of Longan pulp, 13-23 parts of Ziziphus jujuba seeds, 30-40 parts of red dates, and 18-27 parts of raw Hawthorn;

[0010] The compound probiotic is Naqu 4580.

[0011] The Naqu 4580 selected in the present invention has been disclosed in three Chinese patent documents, which are: the patent name is Naqu 4580 and the application of preparations in foods for improving sleep quality, the patent application number is ZL202010705870.4, and the application date is 2022.07.21; the patent name is Naqu 4580 probiotics with antihypertensive activity and its preparations and applications, the patent application number is ZL202010704422.2, and the application date is 2020.07.21; the patent name is Naqu 4580 and the application of its preparations in foods for regulating mood, the patent application number is ZL20201070.44.20.3, and the application date is 2020.07.21. The Naqu 4580 probiotics are composed of thermophilic Streptococcus S709, Lactobacillus paracasei L578 and Lactobacillus helveticus L551.

[0012] The present invention selects a medicinal and edible composition and a compound probiotic to prepare a medicinal and edible fermentation composition, wherein the Cistanche deserticola in the medicinal and edible composition nourishes the kidney and replenishes essence, produces marrow and benefits the brain, so as to treat marrow malnutrition; Polygonatum sibiricum, Codonopsis pilosula, red dates, and longan invigorate the spleen and replenish qi, replenish blood and nourish blood to treat qi and blood deficiency; Ziziphus jujuba seeds calm the mind and soothe the nerves, so as to treat mental malnutrition; Pueraria root, licorice, citron, and hawthorn can promote tendons and activate collaterals, regulate qi and remove blood stasis, so as to treat brain qi stagnation; the whole formula of the medicinal and edible composition plays the functions of nourishing the kidney and spleen, replenishing blood and replenishing qi, calming the mind and soothing the nerves, regulating qi and removing blood stasis, and filling marrow and benefiting the brain. The present invention selects probiotics and finally selects Naqu 4580. Naqu 4580 and the medicinal and edible composition have synergistic effects in inhibiting the activity of acetylcholinesterase, protecting / repairing nerve cells, promoting nerve cells to secrete dopamine, and improving the ability of C8-D1A astrocytes to secrete neurotrophic factor BDNF.

[0013] The medicinal and edible fermentation composition provided by the present invention has the following advantages:

[0014] (1) The food-medicine fermentation composition can inhibit the free radicals from acting on lipids to cause peroxidation reactions and reduce the generation of malondialdehyde; (2) The food-medicine fermentation composition not only protects and repairs nerve cells, but also promotes the secretion of cellular neurotransmitters dopamine and neurotrophic factor BDNF, and plays an important role in the survival, differentiation, growth and development, synaptic plasticity, memory formation and cognitive function of neurons; (3) The food-medicine fermentation composition can inhibit acetylcholinesterase by more than 85%, and is expected to be used to enhance cognitive ability and memory; (4) The results of human trials have confirmed that the elderly can improve their discomfort symptoms such as lack of sleep, memory loss, emotional instability, dizziness and headache after taking the food-medicine fermentation composition obtained by the present invention; (5) The food-medicine fermentation composition is safer after taking, and can effectively avoid the limitations and side effects of chemical drugs.

[0015] Preferably, the weight ratio of the medicine-food homologous composition to the compound probiotics is 100:0.03-0.08; the number of viable bacteria in the compound probiotics is 3×10 10 ~6×10 11 CFU / g.

[0016] The Naqu 4580 bacterial powder is composed of the following components in parts by weight: 92% to 5% of thermophilic streptococcus S70, 10% to 20% of Lactobacillus paracasei L578, and 75% to 88% of Lactobacillus helveticus L551.

[0017] In a second aspect, the present invention provides a method for preparing the above-mentioned medicine-food fermentation composition, the preparation method comprising the following steps:

[0018] S1. Weigh the raw material components of the edible and medicinal composition by weight to obtain a total mixture of the edible and medicinal composition;

[0019] S2. Soaking, beating and sterilizing the total mixture of the medicinal and edible composition in water to obtain a fermentation matrix;

[0020] S3. Inoculate Naqu 4580 into the fermentation matrix, ferment and culture, separate the solid and liquid to obtain the fermentation liquid, and obtain the medicinal and edible fermentation composition.

[0021] The present invention provides a method for preparing a food-medicine fermentation composition through the design of a medicine-food formula, the selection of a fermentation strain, and the comparison of the fermentation advantages of a compound strain. The preparation method utilizes Naqu 4580 to ferment a food-medicine raw material, thereby improving the release of active ingredients of the food-medicine raw material. Meanwhile, fermentation can also decompose macromolecules into small molecules, which are easier to enter the blood after being absorbed by the gastrointestinal tract, pass through the blood-brain barrier, act on the brain, protect / repair nerve cells, and promote the secretion of cellular neurotransmitters dopamine and neurotrophic factor BDNF.

[0022] Preferably, when soaking and beating with water, the material-liquid ratio of the total mixture of the medicinal and edible composition to water is 1:8-9;

[0023] The sterilization temperature is 105-110° C. and the sterilization time is 20-35 minutes.

[0024] Preferably, in step S3, the fermentation culture has a culture temperature of 35.5 to 38.5° C. and a culture time of 36 to 96 hours.

[0025] Preferably, in step S3, after obtaining the fermentation liquid, the steps of coarse filtration to remove the drug residues and centrifugation to obtain the supernatant are also included.

[0026] In a third aspect, the present invention provides the use of a medicinal and edible fermentation composition in the preparation of functional foods or health foods having antioxidant, sleep-improving or memory-improving functions.

[0027] In a fourth aspect, the present invention provides the use of the medicinal and edible fermentation composition in the preparation of medicines for improving sleep quality, preventing cognitive decline or improving cognitive function.

[0028] The dosage form of the food-medicine homologous fermentation composition of the present invention is selected from any one of granules, tablets, capsules, oral liquids, powders or granules. In the present invention, the food-medicine homologous fermentation composition dosage form is an oral liquid as an example for illustration, and other dosage forms can be obtained by conventional technical means in the art. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is a statistical diagram of the survival rate of SH-SY5Y cells in different groups in the protection experiment in Example 1;

[0030] Figure 2 This is a statistical diagram of the survival rate of SH-SY5Y cells in different groups in the repair experiment in Example 1;

[0031] Figure 3 is the dopamine secretion level of nerve cells in different groups in the protection experiment in Example 1;

[0032] Figure 4 is the dopamine secretion level of nerve cells in different groups in the repair experiment in Example 1;

[0033] Figure 5 is the malondialdehyde content in the nerve cells of different groups in the protection experiment in Example 1;

[0034] Figure 6 is the malondialdehyde content in the nerve cells of different groups in the repair experiment in Example 1;

[0035] Figure 7is the level of BDNF secretion by C8-D1A astrocytes in different groups in Example 1;

[0036] Figure 8 The results of the inhibition of acetylcholinesterase by different groups in Example 1;

[0037] Fig. 9 This is the improvement of symptoms of people with sub-healthy brain conditions after taking oral liquid I in Example 1. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0039] The strains used in the present invention are from the following sources:

[0040] The Naqu 4580 selected in the present invention is composed of thermophilic Streptococcus S709, Lactobacillus paracasei L578 and Lactobacillus helveticus L551, wherein Naqu 4580 has been disclosed in 3 Chinese patent documents, of which the information of 1 patent is as follows: Patent name: Naqu 4580 probiotics with antihypertensive activity and its preparation and application, patent application number 202010704422.2; Lactobacillus plantarum LP45: disclosed in the Chinese patent with patent application number 201310587738.8 and invention name "a plant lactobacillus and its application"; Lactobacillus rhamnosus LR519: disclosed in the Chinese patent with patent application number 202011343440.9 and invention name "a strain of Lactobacillus rhamnosus LR519 capable of relieving diarrhea and its composition". The strains used in the present invention have been deposited by the depository institution recognized by the State Intellectual Property Office for patent procedures, and can be identified as a situation where the public can obtain it without requiring deposit.

[0041] The cell sources used in the present invention are as follows:

[0042] SH-SY5Y human neural cells, C8-D1A astrocytes and related supplies were purchased from Wuhan Punosai Biotechnology Co., Ltd.

[0043] The detection method used in the present invention is as follows:

[0044] The dopamine content was detected using a human dopamine enzyme-linked immunosorbent assay ELISA kit; the BDNF content was detected using a human brain-derived neurotrophic factor (BDNF) enzyme-linked immunosorbent assay ELISA kit; the malondialdehyde content was detected using a human dopamine enzyme-linked immunosorbent assay ELISA kit; the reagents used in the Ellman method for the in vitro inhibition activity detection experiment of acetylcholinesterase (AChE) were all purchased from Wuhan Punosai Biotechnology Co., Ltd.

[0045] Example 1

[0046] The present embodiment provides a method for preparing a medicine-food fermentation composition. Furthermore, the effects of the medicine-food fermentation composition obtained by the preparation method on SH-SY5Y cells and C8-D1A astrocytes, as well as the effects on dopamine, malondialdehyde, BDNF and acetylcholinesterase are investigated. The effects of the obtained medicine-food fermentation composition on people with sub-healthy brain symptoms are also investigated through clinical trials.

[0047] 1. A method for preparing a medicinal and edible fermentation composition, the preparation method comprising the following steps:

[0048] S1. Weigh 180g of Cistanche deserticola, 54g of Codonopsis pilosula, 36g of Polygonatum sibiricum, 36g of Pueraria root, 36g of red dates, 18g of raw hawthorn, 18g of citron, 18g of wolfberry, 18g of raw licorice, 18g of longan meat, 13g of jujube kernel to obtain a total mixture of a medicinal and edible composition;

[0049] S2. Add 1780 mL of purified water to the total mixture of the above-mentioned edible and medicinal composition, soak for 18 hours, then beat the mixture, add 1780 mL of purified water, stir evenly, and obtain substrate 1; wherein the total amount of water added twice is 8 times the total weight of the total mixture of the edible and medicinal composition, and sterilize substrate 1 at 105° C. for 30 minutes to obtain a fermentation substrate;

[0050] S3. When the temperature of the fermented substrate drops to 38°C or below, add 0.06% of the total mass of the medicinal and edible composition to the fermentation substrate with the Naqu 4580 fungus powder, and place it in a 37°C environment for 40 hours of static fermentation;

[0051] After the fermentation is completed, the fermentation system is filtered and centrifuged, and the supernatant is filtered with a 1 μm filter membrane to obtain the fermentation liquid, that is, the medicine-food fermentation composition.

[0052] The number of viable bacteria in Naqu 4580 powder is 3×10 11 CFU / g.

[0053] 2. Effects of the medicinal and edible fermentation composition on neurons, glial cells, dopamine, malondialdehyde, BDNF and acetylcholinesterase

[0054] This part investigated the effects of the medicinal and edible fermentation composition on SH-SY5Y cells and C8-D1A astrocytes, and also investigated its effects on dopamine, malondialdehyde, BDNF and acetylcholinesterase. The specific contents are as follows:

[0055] 1. Effects on nerve cells and glial cells

[0056] (1) Recovery of SH-SY5Y cells and C8-D1A astrocytes

[0057] The culture medium of the whole bottle of T25 SH-SY5Y (or C8-D1A) cells purchased from Wuhan Punosai Biotechnology Co., Ltd. was discarded, washed twice with 2 mL PBS, digested with 1 mL trypsin for 2 min, pipetted and aspirated 15 times, and the cell morphology was observed under an inverted microscope. After confirming that the cells became round, transparent in the middle, and uniformly non-adherent to the wall, 3 mL of SH-SY5Y (or C8-D1A) special culture medium was added to terminate the digestion, centrifuged at 1200 r / min for 2 min, the supernatant was discarded, and 3 mL of SH-SY5Y (or C8-D1A) special culture medium was added and pipetted evenly. According to the method of 1 to 3, 1 portion was frozen and 2 portions were continued to be cultured to obtain the resuscitated SH-SY5Y neural cells and C8-D1A astrocytes.

[0058] 2. Establishment of Cell Oxidative Damage Model

[0059] The present invention determines the optimal H2O2 damage concentration by the CCK-8 method:

[0060] (1) Collect SH-SY5Y neural cells and C8-D1A astrocytes that have grown to about 70%-80% density and count the cells. Plate them in a 96-well plate and add 1×10 5 / well, set up 5 to 6 replicate wells in each group and culture for 48 hours.

[0061] (2) Hydrogen peroxide was placed in a special culture medium (DMEM complete medium) for SH-SY5Y (C8-D1A) to adjust the concentration of hydrogen peroxide to 0, 200, 400, 600, 800, 1000, 1200, and 1400 μmoL / L, respectively. More than 200 μl of liquid was added to each well and incubated in an incubator for 8, 24, and 48 hours.

[0062] (3) Remove the original culture medium, add 100 μL of culture medium containing 10% CCK-8 to each well, place in a 37°C incubator for 2 hours, and measure the absorbance at 450 nm to determine the cell activity.

[0063] The experimental results showed that when the H2O2 concentration was 400μmol / L and the injury was carried out for 8h, the survival rate of SH-SY5Y neurons reached 51.3%, and the survival rate of C8-D1A astrocytes reached 54.5%. The injury time was the shortest and the injury effect was better.

[0064] 3. Investigation of the protective and repairing effects on nerve cells

[0065] Oxidative damage is one of the mechanisms of nerve cell aging and the most common factor leading to neurodegenerative diseases. Damage to nerve cells can lead to neurotransmitter imbalance, nerve dysfunction, and symptoms such as forgetfulness, insomnia, emotional instability, and cognitive decline.

[0066] The present invention investigates the protective and repairing effects of the fermented liquid on nerve cells and compares it with the water extract. The specific contents are as follows:

[0067] Five groups were set up, namely normal group, model group, fermentation liquid group, water extract group and donepezil group; the preparation process of the treatment liquid added to different groups was as follows:

[0068] Normal group: no treatment solution was added, and the culture medium was replaced regularly;

[0069] Model group: When damaging cells, 200 μL of 400 μmoL / L hydrogen peroxide was added. After acting on the cells for 2 h, the upper layer of liquid was discarded and replaced with DMEM complete medium, which was changed regularly.

[0070] Fermentation broth group: the fermentation broth prepared in the first part of this implementation was diluted to 3 μL / mL using DMEM complete medium to obtain a fermentation broth group treatment solution;

[0071] Water extract group: add 1780 mL of purified water to the total mixture of the edible and medicinal composition obtained in step S1 of the first part of this implementation, soak for 18 hours, then pulp, add 1780 mL of purified water, stir evenly, and obtain matrix 1; wherein, the total amount of water added twice is 8 times the total weight of the edible and medicinal composition, sterilize matrix 1 at 105°C for 30 minutes, then place it in a 37°C environment and stand for 40 hours, filter and centrifuge the extract, take the supernatant and filter it with a 1 μm filter membrane to obtain a water extract; further, dilute the above water extract to 3 μL / mL using DMEM complete medium to obtain a water extract group treatment solution;

[0072] Donepezil group: Donepezil was prepared into a 0.1 mg / mL stock solution using sterile water, and then diluted to 4 mg / L using DMEM complete medium to obtain the Donepezil group treatment solution.

[0073] (1) Determination of the protective effect on nerve cells

[0074] The protective effects of different groups of treatment solutions on nerve cells were investigated. The specific contents are as follows:

[0075] SH-SY5Y cells were cultured at a concentration of 1×10 5 Each well was inoculated with 200 μL of culture medium in a 96-well plate, cultured for 24 h, and the upper culture medium was discarded.

[0076] Treat cells with different groups of treatment solutions, add 200 μL of treatment solution to each well, and discard the upper layer of treatment solution after 4 h of treatment;

[0077] Add 200 μL of 400 μmoL / L hydrogen peroxide and act on the cells for 2 h. Use 10% CCK8 to act on the cells for 2 h. Measure the absorbance at 450 nm using an enzyme reader, calculate the cell survival rate, and collect the supernatant and store it at -80°C for later use. This is recorded as a protection experiment.

[0078] In the experiment of measuring the protective effect on nerve cells, the statistical graph of the survival rate of SH-SY5Y cells in different groups is shown in Figure 1 .

[0079] (2) Determination of the repair effect on nerve cells

[0080] The repair effects of different groups of treatment solutions on nerve cells were investigated. The specific contents are as follows:

[0081] SH-SY5Y neurons were cultured at a concentration of 1×10 5 Each well was inoculated with 200 μL of culture medium in a 96-well plate, cultured for 24 h, and the upper culture medium was discarded.

[0082] Add 200 μL of hydrogen peroxide at a concentration of 400 μmoL / L to each well, act on the cells for 2 h, and discard the upper liquid;

[0083] 200 μL of treatment solution of different groups was added to each well for repair for 4 hours, and the cells were treated with 10% CCK8 for 2 hours. The absorbance was measured with an enzyme marker at a wavelength of 450 nm, the survival rate of SH-SY5Y cells was calculated, and the supernatant was collected and stored at -80°C for later use, which was recorded as the repair group.

[0084] In the experiment of measuring the repair effect of nerve cells, the statistical graph of the survival rate of SH-SY5Y cells in different groups is shown in Figure 2 .

[0085] like Figure 1 and Figure 2 As shown, in the protection experiment, the survival rate of nerve cells in the fermentation liquid group can reach more than 98%, which is significantly higher than that of nerve cells in the model group (66%); in the repair experiment, the survival rate of nerve cells in the fermentation liquid group is 76%, which is 34% higher than that of the model group; this result shows that the prepared medicine and food fermentation composition has a protective and repairing effect on nerve cells.

[0086] 4. Determination of dopamine, malondialdehyde and BDNF

[0087] Dopamine is a hormone and a neurotransmitter that controls a variety of functions including motor activity, cognition, mood, positively reinforcing behaviors, food intake, and endocrine regulation.

[0088] Malondialdehyde content is an important parameter reflecting the body's antioxidant potential. It can reflect the rate and intensity of lipid peroxidation in the body, and can also indirectly reflect the degree of tissue peroxidation damage.

[0089] Neurotrophic factors are a family of proteins that induce neuronal survival and development. Their members include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), neurotrophin 4 (NT-4), etc. These proteins are potential drug targets for the treatment of diseases such as nerve damage. They belong to a class of growth factors, that is, secreted proteins that can signal specific cells to survive, differentiate or grow. Brain-derived neurotrophic factor (BDNF) can regulate synaptic plasticity and play an important role in the growth and differentiation of neurons. Neurotrophic factors are secreted by target tissues and work by preventing related neurons from initiating programmed cell death, thereby allowing neurons to survive.

[0090] The cell supernatants collected above after being treated with different treatment solutions in the protection experiment and repair experiment were used to detect dopamine, malondialdehyde and BDNF, and the detection method was performed according to the instructions of the corresponding kits.

[0091] (1) Dopamine secretion level

[0092] Among them, in the protection experiment, the dopamine secretion levels of nerve cells in different groups were as follows Figure 3 shown.

[0093] In the repair experiment, the dopamine secretion levels of nerve cells in different groups were as follows Figure 4 shown.

[0094] like Figures 3-4 As shown, the dopamine content of the fermentation broth group in the protection experiment was 132.15 nmol / L, and the dopamine content of the fermentation broth group in the repair experiment was 125.4 nmol / L, which were significantly higher than the dopamine content of the model group in their respective experiments. This result shows that the prepared medicine-food fermentation composition can regulate the dopamine secretion of nerve cells, and can further control multiple functions, including motor activity, cognition, emotion, positive reinforcement behavior, food intake and endocrine regulation.

[0095] (2) Malondialdehyde content

[0096] The statistical diagram of malondialdehyde content in SH-SY5Y cells of different groups in the protection experiment is shown in the figure Figure 5 Shown are the malondialdehyde content in SH-SY5Y cells of different groups in the repair experiment.

[0097] like Figure 5 and Figure 6 As shown, the malondialdehyde contents in the fermentation broth group in the protection experiment and the fermentation broth group in the repair experiment were 1.65 nmol / mL and 1.58 nmol / mL, respectively, which were significantly lower than the malondialdehyde contents in the model group in their respective experiments. This result indicates that the prepared medicine-food fermentation composition can achieve the purpose of anti-oxidation by inhibiting free radicals and slowing down the aging of the body.

[0098] (3) BDNF secretion by C8-D1A astrocytes

[0099] A blank group, a model group, a fermentation liquid group, a water extract group, and a donepezil group were set up in sequence. The preparation methods of the treatment solutions of different groups were as follows:

[0100] Normal group: no treatment solution was added, and the culture medium was replaced regularly;

[0101] Model group: When damaging cells, 200 μL of 400 μmoL / L hydrogen peroxide was added. After acting on the cells for 2 h, the upper layer of liquid was discarded and replaced with DMEM complete medium, which was changed regularly.

[0102] Fermentation broth group: dilute the fermentation broth prepared in the first part of this implementation to 3 μl / mL using DMEM complete medium to obtain a fermentation broth group treatment solution;

[0103] Water extract group: add 1780 mL of purified water to the total mixture of the edible and medicinal composition obtained in step S1 of the first part of this implementation, soak for 18 hours, then pulp, add 1780 mL of purified water, stir evenly, and obtain matrix 1; wherein, the total amount of water added twice is 8 times the total weight of the edible and medicinal composition, sterilize matrix 1 at 105°C for 30 minutes, then place it in a 37°C environment and stand for 40 hours, filter and centrifuge the extract, take the supernatant and filter it with a 1 μm filter membrane to obtain a water extract; further, dilute the above water extract to 3 μl / mL using DMEM complete medium to obtain a water extract group treatment solution;

[0104] Donepezil group: Donepezil was prepared into a 0.1 mg / mL stock solution using sterile water, and then diluted to 4 mg / L using DMEM complete medium to obtain the Donepezil group treatment solution.

[0105] The secretion of BDNF by C8-D1A astrocytes in different groups was measured. The specific contents are as follows:

[0106] C8-D1A astrocytes were cultured at a concentration of 1×105 Each well was inoculated with 200 μL of culture medium in a 96-well plate, cultured for 24 h, and the upper culture medium was discarded.

[0107] Treat cells with different groups of treatment solutions, add 200 μL of treatment solution to each well, and discard the upper layer of treatment solution after 4 h of treatment;

[0108] Add 200 μL of 400 μmoL / L hydrogen peroxide, act on the cells for 2 h, and collect the supernatant to detect the BDNF content.

[0109] The levels of BDNF secreted by C8-D1A cells in different groups are as follows Figure 7 shown.

[0110] like Figure 7 It can be seen that the BDNF content of C8-D1A cells in the fermentation liquid group was 37.33pg / mL, which was significantly higher than 32pg / mL in the model group. This result shows that the prepared medicinal and edible fermentation composition can increase the secretion of BDNF by C8-D1A cells, and can promote the survival, differentiation, growth and development of neurons, synaptic plasticity, memory formation and cognitive function.

[0111] 5. Determination of acetylcholinesterase inhibition rate

[0112] Acetylcholinesterase is a key enzyme that breaks down neurotransmitters (acetylcholine). Inhibiting acetylcholinesterase can reduce the decomposition of acetylcholine and effectively improve memory.

[0113] The in vitro inhibitory activity of acetylcholinesterase (AChE) was tested by the Ellman method. The fermentation stock solution and water extract prepared in the first part of this example (preparation method is the same as the above part) were used as the test samples. Donepezil (concentration of 5 mg / mL) was used as the positive control, and PBS was used as the blank control. During the assay, 10 μL of the sample to be tested was first added to a 96-well plate, followed by 40 μL PBS, 20 μL 2.5 mmol·L-1 5,5-dithio-2-nitrobenzoic acid〔5,5'-dithio-bis(2-nitrobenzoic acid), 5,5-DTNB〕, and 10 μL AChE, followed by oscillation and mixing, pre-incubation at 37°C for 10 min, and then 20 μL 10 mmol·L-1 iodinated thioacetylcholine was added, reacted at 37°C for 10 min, and 30 μL 1% sodium dodecyl sulfate (SDS) was added to terminate the reaction, and the absorbance at a wavelength of 405 nm was measured by an enzyme reader. The percentage of AChE activity inhibition was calculated by the following equation:

[0114] AChE activity inhibition rate (%) = (absorbance value of blank control group - absorbance value of drug group) / absorbance value of control group × 100%.

[0115] The inhibitory effects of the medicinal and edible fermentation composition, the water extract and donepezil on acetylcholinesterase were measured. The results of the inhibitory effects of different groups on acetylcholinesterase are as follows: Figure 8 shown.

[0116] Depend on Figure 8 It can be seen that the acetylcholinesterase inhibition rate of the food-medicine fermentation composition prepared by the present invention can reach 86.68%, and the acetylcholinesterase inhibition rate is increased by 117% compared with the water extract. This result shows that compared with the use of only the food-medicine composition, the food-medicine fermentation composition after fermentation with Naqu 4580 can significantly reduce the activity of acetylcholinesterase. It also shows that the prepared food-medicine fermentation composition can effectively reduce the decomposition of acetylcholine, and has a positive effect on enhancing cognitive ability and memory, so it can be used to improve Alzheimer's disease and cognitive impairment.

[0117] 3. Clinical trial

[0118] This section investigates the improvement effect of the medicinal and edible fermentation composition prepared in the first part of this example on people with sub-healthy brain conditions. The details are as follows:

[0119] The medicinal and edible fermentation composition (i.e., the fermentation liquid) prepared in the first part of this example was dispensed into brown glass bottles at 30 mL / bottle, and then sterilized (105° C., 30 min) to obtain the medicinal and edible fermentation composition oral liquid, recorded as oral liquid I.

[0120] People with sub-healthy brain symptoms were recruited, and questionnaires were conducted before and after the trial as evaluation indicators. The questionnaires were based on the TCM syndrome diagnostic criteria for senile dementia.

[0121] Inclusion criteria:

[0122] (1) Aged ≥ 65 years, regardless of gender.

[0123] (2) Aged ≥ 40 years, with three highs, brain trauma, cerebrovascular disease, chronic heart failure, Parkinson's disease, epilepsy, sleep disorders (including chronic sleep apnea syndrome), excessive obesity (BMI>30), long-term anxiety, depression, smokers and alcoholics, and those complaining of memory loss.

[0124] Note: According to statistics, obesity in middle age, especially abdominal obesity, increases the risk of AD by 59%; heavy drinking in middle age increases the risk of AD by 3 times. Therefore, those who are overly obese and alcoholics are also included.

[0125] (3) Those with good compliance and voluntarily signing the informed consent form.

[0126] (4) Refer to the TCM syndrome diagnostic criteria for senile dementia, and people with two main symptoms (memory loss is essential) and at least two secondary symptoms will be included in the group. Exclusion criteria:

[0127] (1) Those who do not meet the above criteria.

[0128] (2) During the trial period, the subjects’ compliance was poor, which affected the effectiveness and safety evaluators.

[0129] (3) Those under 18 years old, pregnant or lactating women, or those who are allergic to the test samples.

[0130] 2. Directions

[0131] Take twice a day, 30 mL / bottle each time; the dosage cycle is 1 month.

[0132] 3 Monitoring indicators and data

[0133] In view of the sub-health symptoms of the brain, the improvement of the symptoms after the trial was statistically analyzed. The statistical results are as follows: Fig. 9 As shown. Fig. 9 It can be seen that after the people with brain sub-health symptoms tried the oral liquid provided by the present invention for one month, the improvement rate of the memory loss symptom group was 61.2%, the improvement rate of the lack of sleep group was 77.1%, the improvement rate of the emotional instability group was 80.9%, the improvement rate of dizziness and headache symptoms was 88.4%, and the improvement rate of palpitations was 85.7%. In summary, the medicinal and edible fermentation composition provided in this embodiment has a significant improvement effect on the discomfort symptoms of people with brain sub-health.

[0134] Example 2

[0135] This embodiment provides a method for preparing a medicinal and edible fermentation composition. Furthermore, the effects of the medicinal and edible fermentation composition obtained by the preparation method on SH-SY5Y neurons and C8-D1A astrocytes, as well as the effects on dopamine, malondialdehyde, BDNF and acetylcholinesterase were investigated.

[0136] A method for preparing a medicinal and edible fermentation composition, the method comprising the following steps:

[0137] S1. Weigh 90g of Cistanche deserticola, 72g of Polygonatum, 54g of Pueraria, 45g of Codonopsis, 30g of red dates, 27g of raw hawthorn, 27g of citron, 22g of wolfberry, 22g of raw licorice, 22g of longan meat, 23g of jujube kernel to obtain a total mixture of a medicinal and edible composition;

[0138] S2. The total mixture of the above-mentioned medicinal and edible composition is added to 1950 mL of purified water, soaked for 20 hours, and then beaten, 1950 mL of purified water is added, and stirred evenly to obtain substrate 2; substrate 2 is sterilized by wet heat at 110° C. for 20 minutes to obtain a fermentation substrate;

[0139] S3. When the temperature of the fermented substrate drops to 38°C or below, the Naqu 4580 fungus powder is added to the fermentation substrate at a rate of 0.03% of the total mixed mass of the medicinal and edible composition, and the fermentation is cultured in an environment of 35.5°C for 72 hours.

[0140] After the fermentation is completed, the fermentation system is filtered and centrifuged, and the supernatant is filtered with a 1 μm filter membrane to obtain the fermentation liquid, that is, the medicine-food fermentation composition.

[0141] The viable bacterial count of the Naqu 4580 bacterial powder is 6×10 11 CFU / g.

[0142] This example also measured the acetylcholinesterase inhibition rate, the survival rate and dopamine content of neurons in the protection experiment, the survival rate and dopamine content of neurons in the repair experiment, and the effect on the secretion of BDNF by C8-D1A cells according to the method described in Example 1 for the medicinal and edible fermentation composition prepared in this example. The specific results are as follows: The acetylcholinesterase inhibition rate of the medicinal and edible fermentation composition prepared in this example is 85.77%, the survival rate of neurons in the protection experiment is 95.39%, and the dopamine content is 134.2nmol / L, and the survival rate of neurons in the repair experiment is 73.18%, and the dopamine content is 126.7nmol / L. In the fermentation broth group, the BDNF concentration in C8-D1A cells is 36.72pg / mL.

[0143] Example 3

[0144] This embodiment provides a method for preparing a medicinal and edible fermentation composition. Furthermore, the effects of the medicinal and edible fermentation composition obtained by the preparation method on SH-SY5Y neurons and C8-D1A astrocytes, as well as the effects on dopamine, malondialdehyde, BDNF and acetylcholinesterase were investigated.

[0145] A method for preparing a medicinal and edible fermentation composition, the method comprising the following steps:

[0146] S1. Weigh 130g of Cistanche deserticola, 60g of Polygonatum, 45g of Pueraria, 65g of Codonopsis, 40g of red dates, 22g of raw hawthorn, 22g of citron, 27g of wolfberry, 27g of raw licorice, 27g of longan meat, 18g of jujube kernel to obtain a total mixture of a medicinal and edible composition;

[0147] S2. Add 1930 mL of purified water to the total mixture of the above-mentioned medicinal and edible composition, soak for 15 hours, then beat the mixture, add 1930 mL of purified water, stir evenly, and obtain matrix 3; wherein the total amount of water added twice is 8 times the total weight of the total mixture of the medicinal and edible composition, and sterilize the matrix 3 at 108°C for 35 minutes to obtain a fermentation matrix;

[0148] S3. When the temperature of the fermented substrate drops to 38°C or below, the Naqu 4580 fungus powder is added to the fermentation substrate at a rate of 0.08% of the total mass of the medicinal and edible composition, and the mixture is placed in an environment of 38.5°C and allowed to ferment for 36 hours;

[0149] After the fermentation is completed, the fermentation system is filtered and centrifuged, and the supernatant is filtered with a 2 μm filter membrane to obtain a fermentation liquid, that is, the medicinal and edible fermentation composition;

[0150] The viable bacterial count of the Naqu 4580 bacterial powder is 3×10 10 CFU / g. .

[0151] This example also measures the acetylcholinesterase inhibition rate, the survival rate and dopamine content of neurons in the protection experiment, the survival rate and dopamine content of neurons in the repair experiment, and the effect on the secretion of BDNF by C8-D1A cells according to the method described in Example 1 for the medicinal and edible fermentation composition prepared in this example. The specific results are as follows: In this example, the acetylcholinesterase inhibition rate of the fermentation broth was 87.13%, the survival rate of neurons in the fermentation broth was 93.18% and the dopamine content was 135.36nmol / L in the protection experiment, and the survival rate of neurons in the fermentation broth was 72.35% and the dopamine content was 127.94nmol / L in the repair experiment. In the fermentation broth group, the BDNF concentration in C8-D1A cells was 37.96pg / mL.

[0152] Example 4

[0153] In view of the effects of the above-mentioned food-medicine fermentation composition in anti-oxidation, improving sleep, protecting / repairing nerve cells, inhibiting acetylcholinesterase activity, promoting the secretion of cellular neurotransmitter dopamine and neurotrophic factor BDNF, and improving brain sub-health, the food-medicine fermentation composition can be further developed into a functional food or health food with anti-oxidation, sleep improvement, memory improvement or brain sub-health improvement functions according to the existing technology in the art, or it can be prepared into a medicine for improving sleep quality, preventing cognitive decline or improving cognitive function, or it can be prepared as a product for protecting brain health.

[0154] Comparative Example 1

[0155] In this comparative example, the edible and medicinal composition was not fermented on the basis of Example 1. The total mixture of the edible and medicinal composition weighed in Example 1 was added with 8 times water and soaked for 2 hours, heated to boiling, and kept slightly boiling for 2 hours, and the decoction was separated. The residue was decocted 3 times according to the law, and the decoctions of each time were combined, and then the decoction was concentrated to an equal volume with the fermentation liquid of Example 1, which was recorded as the decoction. According to the method described in Example 1, the above decoction was tested for its protective and repairing effects on nerve cells and its ability to inhibit acetylcholinesterase.

[0156] The results showed that the decoction prepared in this comparative example had an inhibition rate of 51.28% on acetylcholinesterase, a survival rate of 83.7% in the protection experiment, and a dopamine content of 124.73 nmol / L. In the repair experiment, the survival rate of the nerve cells was 65.6% and the dopamine content was 123.95 nmol / L. The BDNF concentration in C8-D1A cells was 35.88 pg / mL.

[0157] Comparative Example 2

[0158] This comparative example only changes the fermentation agent based on Example 1, using a single strain of Lactobacillus plantarum LP45 to replace Naqu 4580 for fermentation, and the other parameters are not changed. The fermentation liquid finally obtained is recorded as fermentation liquid pair I. Among them, the amount of live bacteria of Lactobacillus plantarum LP45 added during fermentation is consistent with the total amount of live bacteria of Naqu 4580.

[0159] According to the method described in Example 1, the above fermentation broth was tested for its protective and repairing effects on nerve cells and its ability to inhibit acetylcholinesterase.

[0160] The results showed that the fermentation broth had an inhibition rate of 56.7% on acetylcholinesterase in I, a survival rate of 90.96% and a dopamine content of 124.4 nmol / L in the protection experiment, and a survival rate of 71.2% and a dopamine content of 124.01 nmol / L in the repair experiment. The basic efficacy of this comparative example is higher than that of comparative example 3 and comparative example 2, but significantly lower than that of Example 1.

[0161] Comparative Example 3

[0162] This comparative example only changes the fermentation agent based on Example 1, using a single strain of Lactobacillus rhamnosus LR519 instead of Naqu 4580 for fermentation, and the other parameters are not changed. The fermentation broth finally obtained is recorded as fermentation broth pair II. Among them, the amount of live bacteria of Lactobacillus rhamnosus LR519 added during fermentation is consistent with the total amount of live bacteria of Naqu 4580.

[0163] According to the method described in Example 1, the above fermentation broth was tested for its protective and repairing effects on nerve cells and its ability to inhibit acetylcholinesterase.

[0164] The results showed that the fermentation broth had an inhibition rate of 52.96% on acetylcholinesterase in Ⅱ, a survival rate of 87.33% and a dopamine content of 123.67 nmol / L in the protection experiment, and a survival rate of 69.67% and a dopamine content of 123.85 nmol / L in the repair experiment. The BDNF concentration in C8-D1A cells was 34.74 pg / mL. The basic efficacy of this comparative example is lower than the result of Example 1.

[0165] Comparative Example 4

[0166] This comparative example is based on Example 1, only the types of raw materials in the medicine-food homologous composition are changed, and the two medicinal materials of Polygonatum sibiricum and Puerariae Radix are removed, and the other preparation parameters are not changed, and the obtained fermentation liquid is recorded as fermentation liquid pair III. Among them, the specific changes of the formula are: 180g of Cistanche deserticola, 54g of Codonopsis pilosula, 36g of red dates, 18g of raw hawthorn, 18g of citron, 18g of wolfberry, 18g of raw licorice, 18g of longan pulp and 13g of spiny jujube kernel.

[0167] On the basis of Example 1, only the types of raw materials in the edible and medicinal composition were changed, and only two raw materials, Pueraria lobata and Polygonatum sibiricum, were added. The ratio of the two raw materials was the same as that in Example 1. The total weight of the prepared edible and medicinal composition was consistent with that of Example 1. The other preparation parameters were not changed. The prepared fermentation broth was recorded as fermentation broth pair IV.

[0168] According to the method described in Example 1, the inhibitory ability of the fermentation broth pair III and the fermentation broth pair IV on acetylcholinesterase was tested.

[0169] The results showed that the inhibition rate of fermentation broth pair III on acetylcholinesterase was 67.13%; the inhibition rate of fermentation broth pair IV on acetylcholinesterase was 30.72%. The inhibition rates of fermentation broth pair III and fermentation broth pair IV on acetylcholinesterase were significantly lower than those of fermentation broth in Example 1.

[0170] Comparative Example 5

[0171] This comparative example only changes the leavening agent on the basis of 1 of the embodiment, and replaces the "Lactobacillus paracasei L578" of thermophilic Streptococcus S709, Lactobacillus paracasei L578 and Lactobacillus helveticus L551 in Naqu 4580 bacterial powder with "Lactobacillus plantarum LP45", and all other parameters are not changed, and the fermented liquid finally obtained is recorded as fermented liquid pair V. Wherein, the viable bacteria amount of "Lactobacillus paracasei L578" added during fermentation is identical with the viable bacteria amount of "Lactobacillus plantarum LP45".

[0172] According to the method described in Example 1, the protective and repairing effects of the fermentation broth on nerve cells and the inhibitory ability of acetylcholinesterase were tested.

[0173] The results showed that the inhibition rate of fermentation broth against acetylcholinesterase V was 73.08%, the survival rate of neurons in the protection experiment was 91.77%, and the dopamine content was 128.36 nmol / L. The survival rate of neurons in the repair experiment was 71.35%, and the dopamine content was 123.49 nmol / L.

[0174] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A medicinal and edible fermentation composition, It is characterized in that Its raw materials include medicine-food homologous composition and compound probiotics; The medicine-food composition comprises the following raw materials in parts by weight: 90-180 parts of Cistanche deserticola, 36-72 parts of Polygonatum sibiricum, 36-54 parts of Pueraria root, 45-65 parts of Codonopsis pilosula, 18-27 parts of Citron, 18-27 parts of Lycium barbarum, 18-27 parts of raw Licorice root, 18-27 parts of Longan pulp, 13-23 parts of Ziziphus jujuba seeds, 30-40 parts of red dates, and 18-27 parts of raw Hawthorn; The compound probiotic is Naqu 4580.

2. The medicine-food homologous fermentation composition according to claim 1, It is characterized in that The weight ratio of the medicine-food homologous composition to the compound probiotics is 100:0.03-0.08; the number of live bacteria in the Naqu 4580 bacterial powder is 3×10 10 ~6×10 11 CFU / g.

3. The method for preparing the medicine-food homologous fermentation composition according to claim 1 or 2, It is characterized in that The preparation method comprises the following steps: S1. Weigh the raw material components of the edible and medicinal composition by weight to obtain a total mixture of the edible and medicinal composition; S2. Soaking, beating and sterilizing the total mixture of the medicinal and edible composition in water to obtain a fermentation matrix; S3. Inoculate Naqu 4580 into the fermentation matrix, ferment and culture, separate the solid and liquid to obtain the fermentation liquid, and obtain the medicinal and edible fermentation composition.

4. The method for preparing the medicine-food homologous fermentation composition according to claim 3, It is characterized in that In step S2, when soaking in water, the material-liquid ratio of the total mixture of the medicinal and edible composition to water is 1:8-9; The sterilization temperature is 105-110° C. and the sterilization time is 20-35 minutes.

5. The method for preparing the medicine-food homologous fermentation composition according to claim 3, It is characterized in that In step S3, the fermentation culture has a culture temperature of 35.5 to 38.5° C. and a culture time of 36 to 96 hours.

6. The method for preparing the medicine-food homologous fermentation composition according to claims 3 to 5, It is characterized in that In step S3, after obtaining the fermentation liquid, filtering, centrifugation and sterilization are also included.

7. Use of the medicine-food fermentation composition according to claim 1 or 2 in the preparation of functional foods or health foods with antioxidant, sleep-improving or memory-improving functions.

8. Use of the medicinal and edible fermentation composition according to claim 1 or 2 in the preparation of medicines for improving sleep quality, preventing cognitive decline or improving cognitive function.

9. Use of the medicine-food fermentation composition according to claim 1 or 2 in the preparation of products for protecting brain health.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for treating neurasthenia symptoms by oral administration and preparation method thereof

    CN110193074A

  • Composition for preventing and delaying occurrence and development of senile dementia and application

    CN113577230A

  • Nutritional food as well as preparation method and application thereof

    CN114041592A

  • Medicinal and edible composition fermentation product for improving climacteric symptoms and preparation method thereof

    CN117256844A

  • Method of promoting sleep using topical administration of vasoactive agents

    US20040254202A1

Cited By

  • Cistanche deserticola fermentation liquor capable of improving energy and improving cell aging and preparation method of cistanche deserticola fermentation liquor

    CN121081533A

  • Medicinal and edible composition for synergistically improving AD cognitive and affective disorders through three pathways and preparation method of medicinal and edible composition

    CN121775047A

  • Compositions and methods for improving cognitive dysfunction caused by alzheimer's disease

    CN121775047B

  • Medicinal and edible homologous fermentation composition for promoting sleep and resisting fatigue as well as preparation method and application of medicinal and edible homologous fermentation composition

    CN122272729A